631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Peripheral blood dendritic cell subtype alterations in polycythemia vera Clinical correlations with disease risk and inflammatory profile

ZE74 0282 is a novel JH2 domain JAK2 inhibitor with promising pre clinical activity in JAK2 V617F mutant diseases

Proteomic analysis identifying biomarkers in the progression from essential thrombocythemia to post essential thrombocythemia myelofibrosis A retrospective cohort study

T cell derived TNF α mediates myelofibrosis via JAK2 STAT3 ADAM17 axis in JAK2V617F myeloproliferative neoplasms

Immune Dysregulation and State Transition Transcriptomic Signatures Underlying Pediatric Chronic Myeloid Leukemia Pathogenesis

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Advanced myelofibrosis is marked by loss of NKG2D and DNAM 1 NK activating signaling and increased TIM 3 T CD8 exhaustion

Preclinical and clinical Study of olverembatinib in patients with myeloid lymphoid neoplasms with FGFR1 rearrangement

Immunophenotypic and cytokine profiling reveal robust immunomodulation after dasatinib treatment and identify a subgroup with rapid and deep molecular response in CML patients A multi center prospective study

Differential impacts of Lama4 deficient microenvironment on fitness of BCR ABL1 expressing cells during chronic myeloid leukemia initiation and progression